A5006402876- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Uterine Myomas and Treatments
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Intraperitoneal and Appendiceal Malignancies
- PARP inhibition in cancer therapy
- Endometriosis Research and Treatment
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Cardiac, Anesthesia and Surgical Outcomes
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Economic and Financial Impacts of Cancer
- Enhanced Recovery After Surgery
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Lymphoma Diagnosis and Treatment
- Virus-based gene therapy research
- Palliative Care and End-of-Life Issues
- Metabolism, Diabetes, and Cancer
- Cancer survivorship and care
- Genomics and Rare Diseases
- Cancer, Lipids, and Metabolism
University of Alabama at Birmingham
2016-2025
Gynecologic Oncology Group
2004-2025
University of Alabama at Birmingham Hospital
2023-2025
University of Colorado Denver
2021-2024
O'Neal Comprehensive Cancer Center
2021-2024
St. Vincent's Birmingham
2024
University of Colorado Cancer Center
2021-2024
Community Link
2021-2023
Sidney Kimmel Cancer Center
2023
Johns Hopkins University
2023
Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance initial treatment patients high-grade serous ovarian carcinoma. In an international, phase 3, placebo-controlled trial, we assessed efficacy veliparib added to first-line induction carboplatin and paclitaxel continued monotherapy previously untreated stage III or IV Patients were randomly assigned a 1:1:1 ratio...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States and country’s fifth most common mortality women. A major challenge treating that patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating ovary, fallopian tube, or peritoneum, as these are all managed a similar manner. Most recommendations based on data with subtypes─high-grade serous grade 2/3 endometrioid. The also include specifically for less cancers,...
Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to remains unclear. Download a PDF the Research Summary. In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) stage IVB recurrent in 1:1 ratio receive placebo along combination therapy administration was planned 6 cycles every weeks, followed by up 14 maintenance weeks. were stratified...
PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251 ) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a III trial (SOLO3) tablets nonplatinum chemotherapy cancer who had received at least 2 prior lines platinum-based chemotherapy. PATIENTS AND METHODS In this randomized, open-label trial, were randomly assigned 2:1 to 300...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years diagnosis. A major challenge treating that most have advanced disease at initial The best outcomes are observed whose primary treatment includes complete resection all visible plus combination platinum-based chemotherapy. Research efforts focused on neoadjuvant treatments may improve resectability, as well systemic therapies providing improved long-term...
Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding PD-L1 and PD-L2. We report interim data from patients endometrial cancer (EC) participating phase I trial single-agent dostarlimab. Methods GARNET, an ongoing, single-arm, open-label, intravenous dostarlimab advanced solid tumors, being undertaken at 123 sites. Two cohorts EC were recruited: those dMMR/MSI-H disease (cohort A1) proficient/stable (MMRp/MSS) A2)....
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations diagnosis, evaluation, treatment, and follow-up ovarian, fallopian tube, primary peritoneal cancers. These Insights summarize panel discussion behind recent important updates to guidelines, including revised guidance on alternative chemotherapy regimens advanced age and/or...
To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes interaction between Tie2 receptor angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer.Patients epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive (80 mg/m(2) once [QW], 3 weeks on/1 week off) intravenous 386 10 mg/kg QW (arm A), B), placebo C). The end point was progression-free survival (PFS)....
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations this disease. These Insights detail how the evolution of use PARP inhibitors as maintenance single-agent regimens ovarian cancer informed panel in guidelines.
Abstract Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT ICB unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial atezolizumab (anti-PD-L1) neoadjuvant concurrent (Arm A) vs. B) high-risk node-positive LACC. The primary endpoint the fraction expanded tumor-associated T-cell receptor (TCR) clones blood at day 21 as surrogate measure anti-tumor response. Secondary...
In Brief OBJECTIVE: Guidelines for referring women with pelvic masses suspicious ovarian cancers to gynecologic oncologists have been published jointly by Society of Gynecologic Oncologists (SGO) and the American College Obstetricians Gynecologists (ACOG). They are based on patient age, CA 125 level, physical findings, imaging study results, family history. Although guidelines evidence-based, their predictive value in distinguishing from benign is unknown. METHODS: Chart review factors...
While high-grade serous ovarian carcinoma (HGSOC) is the most common histologic subtype of cancer, significant tumor heterogeneity exists. In addition, chemotherapy induces changes in gene expression and alters mutational profile. To evaluate notion that patients with HGSOC could be better classified for optimal treatment based on expression, we compared genetic variants [by DNA next-generation sequencing (NGS) using a 50 Ion Torrent panel] (using NanoString PanCancer 770 Panel) from 20...